Disease · MONDO_0019783
neovascular glaucoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. neovascular glaucoma. Diseases, record MONDO_0019783. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019783
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Glaucoma, Neovascular, Neovascular glaucoma (disorder), secondary angle-closure glaucoma with rubeosis
- Open Targets
Drugs4
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Phase 3 | ClinicalTrials.gov | 7 | 7 | 6 | Drugs and targets |
| AFLIBERCEPT | CHEMBL1742982 | Protein | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Unknown | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| TRAVOPROST | CHEMBL1200799 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 3 | Vascular endothelial growth factor A inhibitor | Phase 3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| PGF | Placenta growth factor | 1 | Placenta growth factor inhibitor | Phase 3 | https://conductscience.org/library/genes/5228 | Drugs and targets |
| PTGFR | Prostaglandin F2-alpha receptor | 1 | Prostanoid FP receptor agonist | Unknown | https://conductscience.org/library/genes/5737 | Drugs and targets |
Trials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02396316 | Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients | Phase 3 | 54 | 2017-07-21 | Glaucoma, Neovascular | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT03639675 | Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied | Phase 3 | 16 | 2020-02-18 | Glaucoma, Neovascular | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT01225146 | Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) | Phase 1 | 8 | 2017-08-14 | Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01711879 | Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma | Not applicable | 7 | 2021-01-05 | Neovascular Glaucoma | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT04519619 | Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG) | 480 | Neovascular Glaucoma | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov | ||
| NCT02067013 | Analysis of Aqueous and Vitreous Humor | Phase 2 | 45 | Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00441181 | Effects of Travoprost on Neovascular Glaucoma | Not applicable | 40 | Neovascular Glaucoma | TRAVOPROST | Its record names the disease | ClinicalTrials.gov | |
| NCT02914626 | Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study | Phase 3 | 28 | Glaucoma, Neovascular, Ranibizumab | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00384631 | Intravitreal Bevacizumab for Neovascular Glaucoma | Not applicable | 26 | Neovascular, Glaucoma | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01370135 | Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma | Not applicable | 20 | Neovascular Glaucoma, Rubeosis | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 13
See all 13 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cohort 1 vs Cohort 2: serious adverse events | 0 of 6 | 0 of 2 | 8 | NCT01225146 | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: Incidence of Adverse Events | 3 of 3 | 4 of 4 | 7 | NCT01711879 | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: deaths from any cause | 1 of 3 | 0 of 4 | 7 | NCT01711879 | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: serious adverse events | 1 of 3 | 0 of 4 | 7 | NCT01711879 | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: Number of Patients in Each, Group A and Group B, Gaining > 5 Letters on Visual Acuity | 2 of 3 | 0 of 3 | 6 | NCT01711879 | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: Number of Patients Losing > 5 Letters on Visual Acuity in Each Group A and Group B | 0 of 3 | 0 of 3 | 6 | NCT01711879 | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: Number of Patients With Need for Surgical Intervention | 0 of 3 | 0 of 3 | 6 | NCT01711879 | Trial comparisons |
| Aflibercept With Laser vs Aflibercept: Number of Participants With Need for Additional IOP Lowering Medications | 0 of 2 | 0 of 4 | 6 | NCT01711879 | Trial comparisons |
Papers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019783
GET https://conductscience.org/api/diseases/v1/MONDO_0019783/drugs